Author:
Lee Po-Hsin,Chiang Chun-Ju,Tseng Jeng-Sen,Zheng Zhe-Rong,Chen Kun-Chieh,Chu Cheng-Hsiang,Huang Yen-Hsiang,Hsu Kuo-Hsuan,Lee Wen-Chung,Yang Tsung-Ying,Liu Tsang-Wu,Hsia Jiun-Yi,Chang Gee-Chen
Abstract
IntroductionFor patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits.MethodsThis retrospective cohort study was conducted on the database of the National Taiwan Cancer Registry. We analyzed patients with T2aN0 stage IB lung adenocarcinoma (re-classified by AJCC 8th edition) diagnosed during the period from January 2011 to December 2017. They were divided into two groups: (1) group 1: tumor <=3 cm with visceral pleural invasion (VPI); (2) group 2: tumor >3 cm, but <=4 cm. Overall survival (OS) and cancer specific survival (CSS) were evaluated. Risk factors for survival were determined.ResultsA total of 2,100 patients with T2aN0 stage IB lung adenocarcinoma (1,265 in group 1 and 835 in group 2) were enrolled for study. The proportions of patients receiving adjuvant chemotherapy in group 1 and 2 were 39.1% and 68.6%, respectively. Amongst group 1 patients, adjuvant chemotherapy was not an independent risk factor for OS and CSS. Amongst group 2 patients, high-grade histologic findings and receiving sublobar resection were two risk factors for poorer survival. Adjuvant chemotherapy was also associated with an OS (adjusted hazard ratio (aHR), 0.52; 95% confidence interval (CI), 0.38-0.72; P<0.001) and CSS (aHR, 0.54; 95% CI, 0.37-0.78; p=0.001) benefit regardless of the presence or absence of risk factors.ConclusionFor patients with T2aN0 stage IB lung adenocarcinoma, adjuvant chemotherapy improved OS and CSS in those with tumors >3 cm, but <=4 cm.For patients with tumors <=3 cm with VPI, adjuvant chemotherapy had no survival benefit.
Reference36 articles.
1. Cancer statistics, 2021;Siegel Rebecca;CA Cancer J Clin,2021
2. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer: American college of chest physicians evidence-based clinical practice guidelines;Howington;Chest,2013
3. Local recurrence following lung cancer surgery: Incidence, risk factors, and outcomes;Fedor;Surg Oncol,2013
4. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer;Scagliotti;J Natl Cancer Inst,2003
5. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer;N Engl J Med,2004
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献